Premium
Single agent palliative chemotherapy for end‐stage Hodgkin's disease
Author(s) -
Mead Graham M.,
Harker W. Graydon,
Kushlan Paula,
Rosenberg Saul A.
Publication year - 1982
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19820901)50:5<829::aid-cncr2820500504>3.0.co;2-r
Subject(s) - medicine , chemotherapy , palliative chemotherapy , stage (stratigraphy) , disease , surgery , palliative treatment , oncology , paleontology , biology
Abstract We have retrospectively studied responses to single agent chemotherapy in a group of patients with end‐stage Hodgkin's disease, most of whom had been treated with and had failed two combination chemotherapy regimens. Despite the terminal nature of their illness, many patients enjoyed excellent symptomatic relief from their disease with minimal treatment‐related morbidity. Data is presented on 13 such patients treated for a minimum period of six months with a variety of single agents, and provide guidelines for the most effective use of this treatment modality.